# Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

> **NCT01505569** · NA · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 44 (actual)

## Conditions studied

- Ewing's Family Tumors
- Renal Tumors
- Hepatoblastoma
- Rhabdomyosarcoma
- Soft Tissue Sarcoma
- Primary Malignant Brain Neoplasms
- Retinoblastoma
- Medulloblastoma
- Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)
- Atypical Teratoid/Rhabdoid Tumor (AT/RT)
- CNS Tumors
- Germ Cell Tumors

## Interventions

- **DRUG:** Ifosfamide
- **DRUG:** Etoposide
- **DRUG:** Mesna
- **BIOLOGICAL:** G-CSF
- **DRUG:** Busulfan
- **DRUG:** Melphalan
- **DRUG:** Thiotepa
- **BIOLOGICAL:** Autologous stem cell infusion
- **RADIATION:** Radiation
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **PROCEDURE:** Leukapheresis
- **DRUG:** Anti-seizure prophylaxis
- **DRUG:** Ursodiol

## Key facts

- **NCT ID:** NCT01505569
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-20
- **Primary completion:** 2024-02-01
- **Final completion:** 2024-02-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01505569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01505569, "Auto Transplant for High Risk or Relapsed Solid or CNS Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01505569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*